

anti-inflammatoxy and immuno-therapy - all results

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
Immunosuppressants drugs	38 studies ¹	demonstrated 44			
Immunostimulants drugs	27 studies ²	suggested 26			
corticosteroids	16 studies ³		inconclusive results for : death D28 ; deaths ; deaths (time to event analysis only) ; clinical deterioration ; clinical improvement ; clinical improvement (14-day) ; clinical improvement (time to event analysis only) ; death or ventilation ; hospital discharge ; mechanical ventilation ; serious adverse events ; superinfection	suggested 4.9-fold increase in radiologic improvement (14-day) but the degree if certainty is unassessable	
anti-inflammatory therapies	4 studies ⁴		inconclusive results for : death D28 ; deaths ; clinical deterioration ; clinical improvement (28-day) ; clinical improvement (time to event analysis only) ; hospital discharge ; mechanical ventilation ; serious adverse events ; adverse events	suggested 10.3-fold increase in clinical improvement but the degree if certainty is unassessable suggested 10.3-fold increase in clinical improvement (14-day) but the degree if certainty is unassessable suggested 6.7-fold increase in clinical improvement (7-day) but the degree if certainty is unassessable	

Uncertain results are statistically significant results but obtain in trial with high risk of bias.

Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

Notes

¹COV-BARRIER (critically ill), 2022 (NCT04421027) ; Amra, 2021 (IRCT20170207032444N3) ; Fakharian, 2021 (IRCT20151227025726N2) ; Hamed, 2021 () ; Kumar, 2021 (CTRI/2020/05/024959) ; Les-cure (Sarilumab 200mg), 2021 (NCT04327388) ; Les-cure (Sarilumab 400mg), 2021 (NCT04327388) ; MARIPOSA, 2021 (NCT04363736) ; Rashad, 2021 (NCT04519385) ; REMAP-CAP (tocilizumab), 2021 (NCT02735707) ; REMAP-CAP sarilumab, 2021 (NCT02735707) ; Rosas (REMDACTA), 2021 (NCT04409262) ; Singh (TD-0903 10mg), 2021 (NCT04402866) ; Singh (TD-0903 1mg), 2021 (NCT04402866) ;

Singh (TD-0903 3mg), 2021 (NCT04402866); Talaschian, 2021 (IRCT20081027001411N4); Veiga, 2021 (NCT04403685); ACTIV-1 abatacept, 2020 (NCT04593940); ACTIV-1 cenicriviroc, 2020 (NCT04593940); CAN-COVID, 2020 (NCT04362813); Cao, 2020 (); CORIMUNO-TOCI-1 (Group 1), 2020 (NCT04331808); CORIMUNO-TOCI-ICU (Group 2), 2020 (NCT04331808); COVACTA (Rosas), 2020 (NCT04320615); ACTIV-1 infliximab, 0 (NCT04593940); DEVENT, 0 (NCT04377620); NCT04377750 (HMO-0224-20), 0 (NCT04377750); sarilumab Sanofi phase 3 outside US, 0 (); sarilumab Sanofi phase 3 US, 0 (NCT04315298); Tziolos, 2021 (); Andrew, 2020 (); ARI-RAF (Della-Torre), 2020 (); Biran, 2020 (); Mathilde, 2020 (); Rojas-Martel, 2020 (); Rossotti, 2020 (); Somers, 2020 (); TOCI-RAF Study Group (Campochiaro), 2020 ()

²CAPSID, 2021 (NCT04433910); CP-COVID-19, 2021 (NCT04332835); Darazam (COVIFERON Interferon beta-1a), 2021 (NCT04343768); Darazam (COVIFERON Interferon beta-1b), 2021 (NCT04343768); Kalil (ACTT-3), 2021 (NCT04492475); Lopardo, 2021 (NCT04494984); O'Donnell, 2021 (NCT04359810); Pouladzadeh, 2021 (IRCT20200310046736N1); Raman, 2021 (CTRI/2020/06/026222); RECOVER, 2021 (EudCT 2020-001632-10); REMAP-CAP (plasma), 2021 (NCT02735707); Sekine (PLACOVID), 2021 (NCT04547660); AlQahtani, 2020 (NCT04356534); Davoudi-Monfared, 2020 (IRCT20100228003449N2); Gharebaghi, 2020 (IRCT20200501047259N1); ILBS-COVID-02 (Bajpai M), 2020 (NCT04346446); Li, 2020 (ChiCTR2000029757); PICP19 (Ray), 2020 (CTRI/2020/05/025209); PlasmAr, 2020 (NCT04344535); Rahmani, 2020 (IRCT20100228003449N2); Rasheed, 2020 (); Tabarsi, 2020 (IRCT20151227025726N2); Duan, 2020 (); Hegerova, 2020 (); Sean, 2020 (); Bihariesingh-Sanchit (SuriCovid), 2021 (ISRCTN18304314); Joyner, 2020 (NCT04338360)

³COVID STEROID 2, 2021 (NCT04509973); Jamaati, 2021 (IRCT20151227025726N1); Munch (COVID-STERIOD), 2021 (NCT04348305); Rashad, 2021 (NCT04519385); CAPE-COVID, 2020 (NCT02517489); CODEX (Tomazini), 2020 (NCT04327401); DEXA-COVID19, 2020 (NCT04325061); Edalatifard, 2020 (IRCT20200404046947N1); Farahani, 2020 (IRCT20200406046963N1); REMAP-CAP, fixed 7-day course, 2020 (NCT02735707); REMAP-CAP, shock-dependent course, 2020 (NCT02735707); Steroids-SARI, 2020 (NCT04244591); Jianfeng, 2020 (); Raef, 2020 (); Tomasz, 2020 (); Lu, 2020 ()

⁴COLCHIVID, 2021 (NCT04367168); Shi, 2020 (NCT04288102); Shu, 2020 (ChiCTR2000031494); Brunetti, 2020 ()